IP Library › Granted Patent US 10,543,215
Granted Patent B2
US 10,543,215 · App. 15/578,305 · Granted Jan 28, 2020

Combination therapy of cardiac myosin activator and sinus node if current inhibitor

Inventors: Robert Andrew Donald Scott (Thousand Oaks, CA); Scott Wasserman (Newbury Park, CA)
Assignee: AMGEN INC.
A61K31/55A61K9/2013A61K9/2054A61K31/496A61K45/06A61P9/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,215
App. No.
15/578,305
Granted
Jan 28, 2020
Kind
B2
Abstract

Disclosed herein are combination therapies for the treatment of heart failure using a cardiac myosin activator, such as omecamtiv mecarbil, and a sinus node If current inhibitor, such as ivabradine. Also disclosed herein are compositions comprising a cardiac myosin activator and a sinus node If current inhibitor.

Claims (6)

1. A method of treating a subject suffering from heart failure comprising administering to the subject omecamtive mecarbil, or a pharmaceutically acceptable salt or hydrate thereof, and ivabradine, or a pharmaceutically acceptable salt or hydrate thereof, wherein the omecamtiv mecarbil or pharmaceutically acceptable salt of hydrate thereof is administered in a total daily amount of 12.5 mg to 75 mg, and the ivabradine or pharmaceutically acceptable salt or hydrate thereof is administered in a total daily amount of 2.5 mg to 20 mg.

2. The method of claim 1 , wherein the omecamtiv mecarbil or pharmaceutically acceptable salt or hydrate thereof is administered orally.

3. The method of claim 1 , wherein the ivabradine or pharmaceutically acceptable salt or hydrate thereof is administered orally.

4. The method of claim 1 , wherein the subject suffers from congestive heart failure.

5. The method of claim 1 , wherein the subject suffers from systolic heart failure.

6. The method of claim 1 , wherein the subject suffers from heart failure with reduced left ventricular ejection fraction.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021
From: AMGEN INC.
To: AMGEN INC.; CYTOKINETICS, INC.
Reel/Frame 057417/0671 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2017
From: SCOTT, ROBERT ANDREW DONALD; WASSERMAN, SCOTT
To: AMGEN INC.
Reel/Frame 044420/0486 →
Continuity (2)
Provisional Application 62185306 · Jun 26, 2015
Related Publication 20180140611A1 · May 24, 2018
Cited By (8)
US 12,194,039 US 12,221,417 US 12,269,811 US 12,275,704 US 12,295,952 US 12,442,027 US 12,583,821 US 12,612,366